Cellebrite DI Ltd. (NASDAQ:CLBT) Stock Position Lowered by Y.D. More Investments Ltd

Y.D. More Investments Ltd decreased its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 10.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 301,734 shares of the company’s stock after selling 37,016 shares during the quarter. Y.D. More Investments Ltd owned 0.15% of Cellebrite DI worth $6,647,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Quarry LP acquired a new stake in shares of Cellebrite DI during the third quarter worth approximately $27,000. Advisors Asset Management Inc. boosted its position in Cellebrite DI by 130.5% during the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after purchasing an additional 1,742 shares during the last quarter. Pathway Financial Advisers LLC grew its stake in Cellebrite DI by 1,583.8% in the third quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after purchasing an additional 4,118 shares in the last quarter. R Squared Ltd bought a new stake in shares of Cellebrite DI in the 4th quarter valued at approximately $100,000. Finally, Venturi Wealth Management LLC increased its holdings in Cellebrite DI by 28.6% in the third quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company’s stock worth $152,000 after buying an additional 2,000 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Stock Performance

Shares of CLBT opened at $25.46 on Wednesday. The firm’s 50-day simple moving average is $21.87 and its two-hundred day simple moving average is $18.54. Cellebrite DI Ltd. has a fifty-two week low of $8.91 and a fifty-two week high of $25.95.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.05. The company had revenue of $106.90 million during the quarter, compared to the consensus estimate of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. During the same quarter in the prior year, the firm posted $0.09 EPS. Cellebrite DI’s quarterly revenue was up 27.0% compared to the same quarter last year. As a group, equities analysts expect that Cellebrite DI Ltd. will post 0.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Craig Hallum lifted their price objective on Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Needham & Company LLC boosted their price objective on Cellebrite DI from $21.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. raised their target price on Cellebrite DI from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Cellebrite DI has an average rating of “Buy” and a consensus price target of $21.57.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.